Discover open access scientific publications

Search, annotate, share and cite publications

Publications by V. K. T. Alagappan

P253 NVA237 Once Daily Offers Rapid and Clinically Meaningful Bronchodilation in COPD Patients That Is Maintained for 24 H: The GLOW1 Trial

Thorax

Pulmonary

Respiratory Medicine

2011

English

Related publications

Once-Daily Triple Therapy in Patients With COPD: Patient-Reported Symptoms and Quality of Life

English

Is Difficult Asthma Still Clinically Meaningful?

European Respiratory Journal

English

Efficacy and Safety of Fluticasone Furoate 100 Μg Once-Daily in Patients With Persistent Asthma: A 24-Week Placebo and Active-Controlled Randomised Trial

English

Efficacy and Safety of Once-Daily QVA149 Compared With the Free Combination of Once-Daily Tiotropium Plus Twice-Daily Formoterol in Patients With Moderate-To-Severe COPD (QUANTIFY): A Randomised, Non-Inferiority Study

English

Clinical Benefit of Fixed-Dose Dual Bronchodilation With Glycopyrronium and Indacaterol Once Daily in Patients With Chronic Obstructive Pulmonary Disease: A Systematic Review

International Journal of COPD

English

Latanoprost Administered Once Daily Caused a Maintained Reduction of Intraocular Pressure in Glaucoma Patients Treated Concomitantly With Timolol.

British Journal of Ophthalmology

Molecular Neuroscience

English

Indacaterol, a Novel Inhaled 2-Agonist, Provides Sustained 24-H Bronchodilation in Asthma

European Respiratory Journal

English

Clinically Meaningful Change Estimates for the Six-Minute Walk Test and Daily Activity in Individuals With Chronic Heart Failure

Cardiopulmonary Physical Therapy Journal

English

Efficacy of a New Once-Daily Long-Acting Inhaled 2-Agonist Indacaterol Versus Twice-Daily Formoterol in COPD

English

Amanote Research

Discover open access scientific publications

Search, annotate, share and cite publications

Publications by V. K. T. Alagappan

P253 NVA237 Once Daily Offers Rapid and Clinically Meaningful Bronchodilation in COPD Patients That Is Maintained for 24 H: The GLOW1 Trial

Related publications

Once-Daily Triple Therapy in Patients With COPD: Patient-Reported Symptoms and Quality of Life

Is Difficult Asthma Still Clinically Meaningful?

Efficacy and Safety of Fluticasone Furoate 100 Μg Once-Daily in Patients With Persistent Asthma: A 24-Week Placebo and Active-Controlled Randomised Trial

Efficacy and Safety of Once-Daily QVA149 Compared With the Free Combination of Once-Daily Tiotropium Plus Twice-Daily Formoterol in Patients With Moderate-To-Severe COPD (QUANTIFY): A Randomised, Non-Inferiority Study

Clinical Benefit of Fixed-Dose Dual Bronchodilation With Glycopyrronium and Indacaterol Once Daily in Patients With Chronic Obstructive Pulmonary Disease: A Systematic Review

Latanoprost Administered Once Daily Caused a Maintained Reduction of Intraocular Pressure in Glaucoma Patients Treated Concomitantly With Timolol.

Indacaterol, a Novel Inhaled 2-Agonist, Provides Sustained 24-H Bronchodilation in Asthma

Clinically Meaningful Change Estimates for the Six-Minute Walk Test and Daily Activity in Individuals With Chronic Heart Failure

Efficacy of a New Once-Daily Long-Acting Inhaled 2-Agonist Indacaterol Versus Twice-Daily Formoterol in COPD